Neurodegenerative disorders like Alzheimer's disease and Parkinson's disease are characterized by the progressive atrophy and loss of neuronal function.
Lack of knowledge of the essential molecular pathways that cause neurodegeneration is one of the major barriers to the development of neuroprotective medicines for Parkinson's disease and other neurodegenerative illnesses.
A deeper understanding of the diseases' molecular processes is urgently required.
The lack of suitable in vitro models is a significant barrier to the creation of innovative neuroprotective therapies and the identification of early illness biomarkers.
Furthermore, the majority of the ones that are available do not have active neuron-glia interactions. However, it is generally known that astrocytes are essential to both a healthy brain and to pathology, therefore their absence affects the applicability of these models.
Learn more about the neurodegenration with the help of the given link:
